建议有阿片类药物过量危险因素的患者使用纳洛酮鼻喷雾剂。然而，癌症患者对纳洛酮处方的看法和信念以及他们自我感知的服药过量风险尚未得到充分研究。为了确定有服药过量风险且认为纳洛酮有益的癌症患者的比例。2020 年 7 月至 2022 年 4 月期间，我们调查了 150 名成人来自美国三级癌症中心支持性护理流动诊所的患者接受了纳洛酮鼻喷雾剂的联合处方。我们测量了患者对服用过量危险因素的了解、态度、信念以及接受的纳洛酮教育。分析了有益组与无益组之间的风险因素。该调查通过纸质或电话采访的方式进行。在 150 名患者中，55% 是男性，70% 是白人，81% 患有晚期癌症。大多数患者认为纳洛酮是有益的（100/150，67%）。与非受益组相比，受益组中更多的患者同意同时使用酒精（100% vs. 90%；p=0.004）或镇静药物（96% vs.85%；p=0.04）与阿片类药物可能会导致用药过量，并且在家中使用纳洛酮感到安全（95% 对比 60%；p<0.0001）。来自非受益组的更多患者将纳洛酮处方与涉嫌滥用阿片类药物相关联（12/50 vs. 8/100；p=0.01），而较少的患者对其护理人员施用纳洛酮的能力有信心（69% vs. 95） %;p<0.0001)。大多数患者了解纳洛酮的好处，并感到在家中使用纳洛酮是安全的。需要进行更多研究来确定知识差距，并为那些认为无益的人制定教育策略。版权所有 © 2024。由 Elsevier Inc. 出版。

Naloxone nasal spray is recommended for patients with risk factors for opioid overdose. However, cancer patients' perceptions and beliefs regarding naloxone prescriptions and their self-perceived risks for overdose are understudied.To determine the proportion of cancer patients at risk for overdose who perceived naloxone as beneficial.Between July 2020 and April 2022, we surveyed 150 adult patients from the supportive care ambulatory clinic at a tertiary cancer center in the United States who received a co-prescription of naloxone nasal spray. We measured patients' knowledge of overdose risk-factors, attitudes, beliefs, and education received on naloxone. Risk-factors between beneficial vs. non-beneficial groups were analyzed. The survey was administered on paper or via a telephone interview.Of the 150 patients, 55% were male, 70% were white, and 81% had advanced cancer. The majority of patients believed naloxone was beneficial (100/150, 67%). When compared to the non-beneficial group, more patients from the beneficial group agreed that the concurrent use of alcohol (100% vs. 90%;p=0.004) or sedating drugs (96% vs.85%;p=0.04) with opioids could result in overdoses and felt safe having naloxone at home (95% vs. 60%;p<0.0001). More patients from the non-beneficial group associated naloxone prescription with being suspected of misusing opioids (12/50 vs. 8/100;p=0.01), and fewer had confidence in their caregivers' ability to administer naloxone (69% vs. 95%;p<0.0001).Most patients understood the benefits of naloxone and felt safe having one at home. More research is needed to identify knowledge gaps and develop educational strategies for those who find it non-beneficial.Copyright © 2024. Published by Elsevier Inc.